SPI Pharma taps Thomson as CEO

By Jenni Spinner contact

- Last updated on GMT

(IrinaBraga/iStock via Getty Images Plus)
(IrinaBraga/iStock via Getty Images Plus)

Related tags: SPI Pharma, Excipients, Ceo, new hires, Basf

The pharma ingredients company has named veteran Scott Thomson, a 29-year veteran with chemicals firm BASF, to its executive leadership team.

In the nearly 30 years before coming on board SPI Pharma, Thomson served as an international executive with a record of strategy development and execution, as well as operational management. While with BASF, Thompson filled a variety of leadership roles in both North America and in Germany.

Thomson’s positions with BASF include senior vice president of the company’s Global Pharmaceutical Solutions Business. Most recently, he served as the senior vice president of the Care Chemicals Division in North America.

Thomson comes to SPI Pharma with a breadth of experience with pharmaceutical excipients as well as other specialty ingredients. According to SPI Pharma, he also offers a history of developing businesses through high-performance teams and customer partnerships, to help deliver innovative solutions to the marketplace.

Headquartered in Wilmington, Delaware, SPI Pharma serves the global pharmaceutical and nutritional market with solutions designed to help solve even challenging formulation problems. The company services more than 50 countries with manufacture and marketing of excipients, antacid actives, and drug delivery systems for tablets, powders, taste-masked actives and vaccine adjuvants.

SPI Pharma also provides drug development services, with involvement in more than 60 commercially and other items. It is part of ABF Ingredients, backed by parent company Associated British Foods.

SPI Pharma recently presented at the virtual CPhI Festival of Pharma conference. The company discussed the show, excipient and ingredient trends and the potential impact of COVID-19​ with Outsourcing-Pharma in September.

In March, the company announced four additions to its Mannogem line of mannitols​. Mannogem XL Opal, Mannogem XL Ruby, Mannogem Emerald and Mannogem Onyx are intended for use in patient-friendly dosage forms, including orally disintegrating tablets and chewables.

Related news

Related products

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars